KRAS
2 drugsKirsten Rat Sarcoma Viral Oncogene Homolog
Predictive biomarker for patient selection in 4 indications
Understanding KRAS
What it means: KRAS mutations (G12C, G12D, G12V, etc.) lock the protein in active state, driving cell proliferation. Most common oncogene mutation.
Why it matters: KRAS G12C inhibitors (sotorasib, adagrasib) are now available. Other KRAS mutations remain challenging targets.
Testing: Tested via NGS or PCR-based assays. KRAS status also predicts resistance to EGFR antibodies in colorectal cancer.
2
Approved Drugs
4
Indications
2
Companies
KRAS is a precision-medicine biomarker linked to 2 FDA-approved targeted drugs from 2 companies, spanning 4 indications including KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer, KRAS G12C-mutated metastatic colorectal cancer, KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Explore the targeted therapies, indications, testing methods, and companies developing KRAS drugs below.
Search KRAS Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting KRAS
KRAS Indications
KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer KRAS G12C-mutated metastatic colorectal cancer KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) KRAS G12C-mutated locally advanced or metastatic colorectal cancer (CRC)